Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019

March 11, 2019

GAITHERSBURG, Md., March 11, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and year-end 2018 financial and operating results following the close of U.S. financial markets on Monday, March 18, 2019.

Conference call details are as follows:

Date:	March 18, 2019
Time:	4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:	(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode:	9559037
Webcast:	www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates:	Starting at 7:30 p.m. ET, March 18, 2019 until
	7:30 p.m. ET March 25, 2019
Dial-in number:	(855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:	9559037
Webcast:	www.novavax.com, "Investors"/ "Events", until June 18, 2019

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVaxTM, its RSV vaccine for infants via maternal immunization and NanoFluTM, its quadrivalent influenza nanoparticle vaccine. Novavax's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit <u>www.novavax.com</u> and connect with us on <u>Twitter</u> and <u>LinkedIn</u>.

Contact:

Investors Erika Trahan Senior Manager, Investor & Public Relations <u>ir@novavax.com</u> 240-268-2000

Westwicke Partners John Woolford john.woolford@westwicke.com 443-213-0506

Media Sam Brown Andrea Cohen <u>andreacohen@sambrown.com</u> 917-209-7163